Low dose versus high dose stavudine for treating people with HIV infection.
暂无分享,去创建一个
[1] F. Raal,et al. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV‐infected patients: a randomized trial , 2013, HIV medicine.
[2] S. Collins,et al. Why it’s time to say goodbye to stavudine ... everywhere , 2012 .
[3] M. Cotton,et al. Low-dose stavudine trials: a public health priority for developing countries , 2012 .
[4] R. Écochard,et al. Toxicity Associated with Stavudine Dose Reduction from 40 to 30 mg in First-Line Antiretroviral Therapy , 2011, PloS one.
[5] Michael Benatar,et al. HIV neuropathy in South Africans: Frequency, characteristics, and risk factors , 2010, Muscle & nerve.
[6] S. Naicker,et al. Symptomatic hyperlactataemia in adults on antiretroviral therapy: a single-centre experience. , 2008, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[7] E. Delaporte,et al. Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings , 2008, Expert opinion on drug safety.
[8] K. Mounzer,et al. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] K. Buchacz,et al. Changes in Lipid Profile Over 24 Months Among Adults on First-Line Highly Active Antiretroviral Therapy in the Home-Based AIDS Care Program in Rural Uganda , 2008, Journal of acquired immune deficiency syndromes.
[10] Nina Friis-Møller,et al. Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients , 2008, Diabetes Care.
[11] C. Katlama,et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment , 2007, Expert opinion on pharmacotherapy.
[12] S. Gove,et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings , 2006, The Lancet.
[13] S. Knight,et al. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. , 2006, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[14] Ò. Miró,et al. The Impact of Reducing Stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients , 2006, Antiviral therapy.
[15] M. Ingelman-Sundberg,et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz , 2006, Pharmacogenetics and genomics.
[16] Joel E Gallant,et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.
[17] V. Soriano,et al. Reductions in Stavudine Dose Might Ameliorate Mitochondrial-Associated Complications Without Compromising Antiviral Activity , 2005, HIV clinical trials.
[18] P. Sax,et al. Tolerability and Safety of HIV Protease Inhibitors in Adults , 2004, Journal of acquired immune deficiency syndromes.
[19] Joel E Gallant,et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.
[20] P. Reiss,et al. Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors , 2004, HIV medicine.
[21] B. Day,et al. Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective , 2003, Nature Reviews Drug Discovery.
[22] S. Mallal,et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy , 2003, AIDS.
[23] David A. Cooper,et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy , 2003, AIDS.
[24] A. Garg,et al. Lipodystrophy in Human Immunodeficiency Virus-Infected Patients , 2002 .
[25] Carl Peck,et al. Postmarketing drug dosage changes of 499 FDA‐approved new molecular entities, 1980–1999 , 2002, Pharmacoepidemiology and drug safety.
[26] S. Grinspoon,et al. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. , 2002, Metabolism: clinical and experimental.
[27] T. Cihlar,et al. Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir: Comparison with Other Nucleoside Reverse Transcriptase Inhibitors , 2002, Antimicrobial Agents and Chemotherapy.
[28] R. Roche,et al. Effects of antiretroviral drug combinations on the differentiation of adipocytes , 2002, AIDS.
[29] K. Ruxrungtham,et al. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients , 2000, AIDS.
[30] T. Kakuda,et al. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. , 2000, Clinical therapeutics.
[31] P. Reiss,et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy , 1999, The Lancet.
[32] A. Cross,et al. Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3. , 1999, Journal of acquired immune deficiency syndromes.
[33] J. Smeitink,et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway , 1998, AIDS.
[34] D. Cooper,et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance , 1998, The Lancet.
[35] J. Lennox,et al. Benign symmetric lipomatosis associated with protease inhibitors , 1997, The Lancet.
[36] M. Dalakas,et al. Mitochondrial toxicity of antiviral drugs , 1995, Nature Medicine.
[37] A. Cross,et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. , 1995, The Journal of infectious diseases.
[38] A. Cross,et al. Design and implementation of the stavudine parallel-track program. , 1995, The Journal of infectious diseases.
[39] R. Pollard. Randomized double-blind study of combination therapy with didanosine and stavudine in HIV-infected individuals , 1997 .
[40] S. Steinberg,et al. 2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. , 1993, The Journal of infectious diseases.